An efficacy trial of the malaria vaccine SPf66 in Gambian infants - second year follow-up

KA Bojang; SK Obaro; U D'Alessandro; S Bennett; P Langerock; GA Targett; BM Greenwood

doi:10.1016/S0264-410X(97)00159-X

An efficacy trial of the malaria vaccine SPf66 in Gambian infants - second year follow-up

KA Bojang, SK Obaro, U D'Alessandro, S Bennett, P Langerock, GA Targett, BM Greenwood

Research output: Contribution to journal › A1: Web of Science-article › peer-review

Abstract

In 1994, 630 Gambian infants were immunized with three doses of the synthetic polypeptide malaria vaccine SPf66 or with a control vaccine. No significant protection against first or total attacks of malaria was observed among the children who received SPf66. However, the period of follow-up was short. Thus, 532 children were followed for a second malaria transmission season during which 291 episodes of malaria were detected. Protective efficacies of SPf66 against first attacks of malaria and against all attacks of malaria were 8% [95% CI −20%, 30%] and 2% [95% CI −26% 24%] respectively. SPf66 did not provide any significant degree of protection to Gambian infants during a second year of follow-up.

Original language	English
Journal	Vaccine
Volume	16
Issue number	1
Pages (from-to)	62-67
Number of pages	6
ISSN	0264-410X
DOIs	https://doi.org/10.1016/S0264-410X(97)00159-X
Publication status	Published - 1998

Keywords

B780-tropical-medicine
Protozoal diseases
Malaria
Vaccination
SPf66
Efficacy
Gambia
Africa-West

Access to Document

10.1016/S0264-410X(97)00159-X

http://lib.itg.be/pdf/itg/1998/1998vacc0062.pdf

Cite this

@article{40b7ef85349f4a5d9e2f737427b0bce8,

title = "An efficacy trial of the malaria vaccine SPf66 in Gambian infants - second year follow-up",

abstract = "In 1994, 630 Gambian infants were immunized with three doses of the synthetic polypeptide malaria vaccine SPf66 or with a control vaccine. No significant protection against first or total attacks of malaria was observed among the children who received SPf66. However, the period of follow-up was short. Thus, 532 children were followed for a second malaria transmission season during which 291 episodes of malaria were detected. Protective efficacies of SPf66 against first attacks of malaria and against all attacks of malaria were 8% [95% CI −20%, 30%] and 2% [95% CI −26% 24%] respectively. SPf66 did not provide any significant degree of protection to Gambian infants during a second year of follow-up.",

keywords = "B780-tropical-medicine, Protozoal diseases, Malaria, Vaccination, SPf66, Efficacy, Gambia, Africa-West",

author = "KA Bojang and SK Obaro and U D'Alessandro and S Bennett and P Langerock and GA Targett and BM Greenwood",

note = "FTX: Abonnement",

year = "1998",

doi = "10.1016/S0264-410X(97)00159-X",

language = "English",

volume = "16",

pages = "62--67",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - An efficacy trial of the malaria vaccine SPf66 in Gambian infants - second year follow-up

AU - Bojang, KA

AU - Obaro, SK

AU - D'Alessandro, U

AU - Bennett, S

AU - Langerock, P

AU - Targett, GA

AU - Greenwood, BM

N1 - FTX: Abonnement

PY - 1998

Y1 - 1998

N2 - In 1994, 630 Gambian infants were immunized with three doses of the synthetic polypeptide malaria vaccine SPf66 or with a control vaccine. No significant protection against first or total attacks of malaria was observed among the children who received SPf66. However, the period of follow-up was short. Thus, 532 children were followed for a second malaria transmission season during which 291 episodes of malaria were detected. Protective efficacies of SPf66 against first attacks of malaria and against all attacks of malaria were 8% [95% CI −20%, 30%] and 2% [95% CI −26% 24%] respectively. SPf66 did not provide any significant degree of protection to Gambian infants during a second year of follow-up.

AB - In 1994, 630 Gambian infants were immunized with three doses of the synthetic polypeptide malaria vaccine SPf66 or with a control vaccine. No significant protection against first or total attacks of malaria was observed among the children who received SPf66. However, the period of follow-up was short. Thus, 532 children were followed for a second malaria transmission season during which 291 episodes of malaria were detected. Protective efficacies of SPf66 against first attacks of malaria and against all attacks of malaria were 8% [95% CI −20%, 30%] and 2% [95% CI −26% 24%] respectively. SPf66 did not provide any significant degree of protection to Gambian infants during a second year of follow-up.

KW - B780-tropical-medicine

KW - Protozoal diseases

KW - Malaria

KW - Vaccination

KW - SPf66

KW - Efficacy

KW - Gambia

KW - Africa-West

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:A1998YK43700010

U2 - 10.1016/S0264-410X(97)00159-X

DO - 10.1016/S0264-410X(97)00159-X

M3 - A1: Web of Science-article

SN - 0264-410X

VL - 16

SP - 62

EP - 67

JO - Vaccine

JF - Vaccine

IS - 1

ER -

An efficacy trial of the malaria vaccine SPf66 in Gambian infants - second year follow-up

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this